Cite
HARVARD Citation
Roswarski, J. et al. (2018). Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. Leukemia & lymphoma. 59 (6), pp. 1466-1469. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Roswarski, J. et al. (2018). Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. Leukemia & lymphoma. 59 (6), pp. 1466-1469. [Online].